99% High Purity Axitinib Powder CAS: 319460-85-0 For Cancer Therapy

Basic Details:

Product Name: Axitinib
Synonyms: Axitinib (usan);D03218;Axitinib(AG 013736);Axtinib;N-Methyl-2-({3-[(E)-2-

(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzaMide;Inlyta;10mg;Axitinib (TINIBS)
CAS: 319460-85-0
MF: C22H18N4OS
MW: 386.47
EINECS: 1308068-626-2

Melting point 213-215°C
density 1.4
storage temp. -20°C Freezer
solubility DMSO: ≥8mg/mL
color white to tan

Usage And Synthesis
FDA approved axitinib use of treating advanced kidney cancer January 27, 2012, the FDA

approved axitinib for the treatment of advanced kidney cancer (renal cell carcinoma) which

other drugs unanswer . Inlyta is manufactured and sold by Pfizer,and is a oral pill taken

twice a day.
Renal cell carcinoma is a type of tumor originating from the tubular endothelial cells.

Axitinib can prevent certain protein called kinases playing a role in tumor growth and

metastasis .
Axitinib is a small molecule tyrosine kinase inhibitor, effective against multiple targets,

including VEGF receptors 1, 2 and 3.
Dr. Richard Pazdur, hematology and oncology drugs office director of FDA Drug Evaluation

and Research Centre, said: "This is the seven kind of drugs allowed treating metastatic or

advanced renal cell carcinoma since 2005 . Overall, during this time ,record level of drug

development has dramatically changed the treatment of metastatic renal cell carcinoma

paradigm, and offers a variety of treatment options for patients. "
In recent years, the drug has been approved for the treatment of kidney cancer include

sorafenib (2005), sunitinib (2006), temsirolimus(2007), everolimus (2009), bevacizumab

(2009) and pazopanib(2009).

Chemical Properties Off-White Solid

Uses A tyrosine kinase inhibitor; used in cancer therapy.
Uses Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ

and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively.
Uses Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit

with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively.
Uses Axitinib is a tyrosine kinase inhibitor. Axitinib is used in cancer therapy.
Definition ChEBI: An indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl

group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the

treatment of advanced renal cell carcinoma after failure of a first line systemic tr

atment.

Description:
1.Axitinib is also called by its brand name Inlyta. It is a type of drug called a tyrosine kinase inhibitor, which is a cancer growth blocker. It blocks certain proteins called tyrosine kinases from acting on cells. Tyrosine kinases signal to cancer cells to grow.Axitinib blocks different types of tyrosine kinase and is called a multi kinase inhibitor.
It stops cancer cells forming blood vessels, which the cancer needs in order to grow. This is called anti angiogenesis treatment.Axitinib is a treatment for advanced kidney cancer. You may also have it as part of a clinical trial for other cancers including soft tissue sarcoma and thyroid cancer.

2.Axitinib interferes with the growth of some cancer cells.Axitinib is used to treat advanced kidney cancer.Axitinib is usually given after other cancer medicine has been tried without success.

Axitinib may also be used for purposes not listed in this medication guide.Axitinib dose-dependently inhibits tumor growth in MV522 with ED50 value of 8.8 mg/kg twice daily, based on the relationship between dose and the corresponding TGI (tumor growth inhibition).

3.Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma. Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic. Axitinib has yet to be linked to instances of clinically apparent acute liver injury.

Application:
Axitinib is indicated for kidney cancer. Axitinib is a kinase inhibitor shown to inhibit the vascular endothelial receptors (VEGFR-1, VEGFR-2, and VEGFR-3) implicated in angiogenesis and tumor growth leading to cancer progression.Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.